Education · The Consumer Health Walk-Through
You have an idea: a consumer health formula so effective the clinical trials prove it works — measurably better than what's on the shelf. Sprays, foams, liquids, creams, gels — non-pill products people apply or use, spanning cosmetics to medicated OTC. And you're not naïve: you know the giants — L'Oréal, Beiersdorf, Estée Lauder and their class — have legal teams who've watched a hundred founders walk in with the same look. This page walks it the way the consumer health industry actually runs — not a generic tech pipeline, but the real applied-formulation journey: from idea to a stable, safe, provable product, the regulation, the route to shelf, and the deal where you keep a fair piece of the pie instead of getting steam-rolled.
The Honest Picture
Before a single batch is mixed, be precise about what you have and what it takes to become a shelf product. In consumer health, the idea travels through four distinct assets — and they get built in a specific order. A brilliant formula you can't protect is a secret with no lock. A protected formula with no clinical proof is a claim nobody believes. Proof with no route to shelf is a lab result. The order is everything.
The chemistry that works — active ingredients, the delivery system that gets them where they work, and a base that's stable and safe for people to use. This is the molecule, and it is only the start.
The clinical trial that proves it — a real, measurable difference against a proven benchmark, designed so a giant's scientists can't tear it apart. This is what makes anyone actually want it.
The IP that makes it property — a filed provisional, guarded trade secrets, a trademarked brand, a paper trail. This is the lock that turns a good idea into something with a price.
The path to the shelf — your own brand, a licence to a giant, or the hybrid. This is what decides whether you earn a margin, a royalty, or both.
Step One — The Chemistry
The first real stage of the consumer health journey is formulation — turning an idea into a reproducible, stable, manufacturable product. Most founders don't do this alone; they work with a contract formulator or a specialist manufacturer. What matters is understanding the game well enough to direct it.
Contract manufacturers and formulation chemists build and iterate the product for you. You bring the idea and the active; they bring the base, the system, the preservation and the stabilisation. Pick one who knows how to scale, not just bench-test.
Where the actives and raw materials come from matters — availability, cost, compliance and supplier reliability. A formula built on a scarce or banned ingredient dies at the regulatory gate. Verify supply before you fall in love with the recipe.
Two products with the same active can perform completely differently depending on how the active is carried and released — a spray, a foam, a cream and a gel each deliver differently. The delivery system is often the real innovation, and the hard part to replicate.
A formula that works on the bench often misbehaves at scale — pH drifts, separation, viscosity or canister-pressure shifts. The journey from lab sample to reproducible production batch is where a lot of products quietly fail. Budget trial batches, not just a prototype.
Illustrative figures for demonstrating the arithmetic. COGS vary by ingredients, packaging tiers and volume — this is the structure, not an appraisal.
The point of the arithmetic: a brilliant formula is a small part of what a product costs. When you license to a giant, you are monetising the formula and the evidence — not paying for packaging, shelves and ads. That's precisely why licensing can still be the better economic route for a pure formula play.
Step Two — The Proof
Consumer health is an evidence business at the top end. The giants will not take your word that it works — they will ask to see the design of the study, the numbers, and the claims you're lawfully allowed to make. The clinical case is the single most expensive thing you do before the deal, and it is what turns "adjectives" into "a difference."
A clear comparator (ideally a proven benchmark, not water), blinded assessment, a defensible sample size, objective instrumentation where possible, and results a statistician can stand behind. The design is the credibility.
Toxicology, irritancy, sensitisation and compatibility testing before any efficacy claim. A product that works but isn't safe will never reach a shelf. Safety is a gate, not a footnote — and it's part of the evidence, not an afterthought.
The sample size, the p-values, the confidence intervals — a giant's statistician will check. An underpowered or cherry-picked result is worse than no study, because it gives them a clean reason to dismiss the whole idea.
Every claim you print must be backed by the data — "clinically proven," "visible improvement," "reduces appearance of," "soothes." An unsubstantiated claim is a marketing liability today and a regulatory problem tomorrow — and crosses into drug territory if it promises treatment.
Step Three — The Lock
Nothing in this walk-through matters more than the order of two steps: protect first, pitch second. A giant's legal team is extremely good at what it does. The one thing it cannot casually take is a formula that is already owned, filed, documented and under a signed NDA. The protection is the whole difference between a negotiation and a giveaway.
File a provisional patent before any disclosure — even to a potential partner. It establishes your priority date cheaply and buys a year to file the full application. Showing a formula before it's filed is the classic, fatal, avoidable mistake.
A patent discloses the invention in exchange for a time-limited monopoly. A trade secret keeps the composition confidential forever — but only if it stays secret, and only if reverse engineering can't crack it once it's on shelves. Decide per component.
Protect the brand name and identity before someone else does. It's the consumer-facing asset that survives even if the formula is licensed out — part of what you own in every scenario.
A written, signed NDA before the first real disclosure — reviewed by your counsel, not just theirs. Their standard NDA serves them. Push back on the terms before the meeting, not during it. An unsigned meeting is a meeting where your idea is already gone.
Dated, signed records of what you disclosed, to whom and when — lab notebooks, batch records, disclosure logs. If a dispute ever comes, the record of the record is what wins or loses it.
Stage and gate what you reveal. Share the clinical data and the claim — not the recipe. A giant needs to believe it works before it needs to know how it's made. Data leaves the room; the recipe doesn't.
Step Four — The Rules
Unlike a piece of software, a consumer health product lives inside a regulatory system that decides what can go in a unit and what you're allowed to claim about it — market by market, and category by category. The EU, the US, and many other regimes each have their own floor. This is where a "game-changer" product either becomes sellable or quietly becomes illegal — and where cosmetic claims end and drug claims begin.
| The rule | What it governs | Why it matters here |
|---|---|---|
| Cosmetic vs drug | Whether the product is a cosmetic or an OTC drug based on claims and function | The same formula can sit on either side of the line depending on what it promises — this decides the whole regulatory path |
| Allowed ingredients | Which actives and preservatives may legally be used in a market | A product built on a banned or restricted ingredient dies in that market — verify before you formulate |
| Concentration limits | How much of a given active a product may contain | The "effective" dose may need to sit under a legal cap — science vs the rulebook |
| Claims law | What you may and may not claim | Cosmetics claims must be substantiated; any treatment promise can push you into drug territory |
| Label & INCI | Ingredient disclosure, labelling, warnings, allergens | How the product is presented on the unit is itself regulated |
| Product notification | Registering the product before it's placed on the market | A product can't reach a shelf until it's notified/compliant in that jurisdiction |
| The EU floor | EU Cosmetics Regulation (1223/2009) and related rules | One of the strictest globally — the baseline your EU shelf must clear |
| The US floor | US FDA cosmetics law and the MoCRA regime | Different structure and increasingly strict — get the US floor right for that market |
Step Five — The Route
The route decides what you own, what you risk, and what you eventually earn. There are two clean paths and a hybrid that most founders should seriously consider: build your own brand, license the formula to a giant, or produce and sell your own line while licensing internationally and into categories you can't reach. Compare the three side by side.
| Consideration | Build it Yourself | License Out | Hybrid |
|---|---|---|---|
| Ownership & control | Full — the brand, the recipe, the story are yours | Lower — the giant runs the brand; you license | Best of both — your brand at home, licensed abroad |
| Capital & cost | High — manufacturing, regulatory, distribution, marketing all yours | Low — they fund shelves and launches | Moderate — fund your core line, let partners fund the rest |
| Risk | High — a failed launch is your loss | Low — the giant carries most of it | Balanced — core risk is yours, expansion risk is shared |
| Speed to shelf | Slow — every step is on you | Fast — they already own the shelf | Fast internationally, steadier at home |
| Earnings | Highest margin per unit | Royalty on their sales — a piece of a big pie | Margins at home + royalties abroad |
| Best fit | A formula plus the capital and hunger to build a brand | Pure-play monetising the IP, not the brand | Most founders' pragmatic default |
The hybrid exists because both pure paths have a flaw: building everything yourself can burn through capital before the shelf is reached, while licensing everything away can leave you with a royalty and no brand. Keep your own shelf; license the markets and categories you can't win alone.
The Whole Path
Here is the full consumer health pipeline in the order it actually runs — not a tech roadmap, but the applied-formulation sequence. Tap each stage to open its steps. Note the hard dependencies: a product must be stable and safe before it's tested, and protected before it's shown.
The conception and the claim decide everything downstream. Get the position, the benchmark and the format right before the chemistry.
This stage turns an idea into something reproducible, stable and safe. It's where a lot of products quietly fail — at scale, not on the bench.
The clinical case is the credibility, and it's the long pole of the whole journey. Design it to survive their scientists.
This is the step most founders rush past — and the one that decides whether the idea ever has a price. Protect it like the asset it must become.
The formula is global; the shelf is local. Getting the regulatory floor and the category right per market is what lets it be sold or licensed at all.
The route is a capital-and-control decision, not an ego decision. The hybrid is the hedge that keeps a foot in both worlds.
The deal is where the piece of the pie is actually sliced. The stages before it — protection, evidence, route — are what let you walk in holding the knife.
The Counter-Party
You asked the real question: how do you pitch to L'Oréal, Beiersdorf and their class — and avoid being steam-rolled — while still walking out with a fair piece of the pie? The answer is not to fight harder in the room. It's to walk in with two demonstrations and the protections that make steam-rolling expensive.
Open with the clinical result and the proof of ownership. Two things make giants lean in: evidence it works, and evidence you already own it. Never open with adjectives.
They need to believe it before they need to know how it's made. Share efficacy, not composition. The formula stays in the vault; what leaves is proof.
Their standard NDA is written to protect them — thin protection of yours, no teeth. Defence: have your counsel review and counter it before the meeting.
The boilerplate that lets them claim your disclosure overlaps their work — and quietly walk with it. Defence: narrow it to a defined list, require written notice, keep your disclosure documented and dated.
An innocuous document that lets them "assess" — sometimes carrying an invention-assignment or broad-licence clause. Defence: read every assignment clause; ownership never moves in an evaluation.
They slow you to drain your money, then lowball — or charm you and shrink the economics. Defence: your own deadlines, alternatives alive, the hybrid path without them — and every number in writing.
The Big Question
"A fair piece of the pie" is not a vague hope — it's a calculation. For a licensed formula, your piece is a royalty on net sales plus upfront fees and milestones, multiplied across the licensed markets and years. Here is a worked example of a consumer health licence, using the same licensing logic as every deal on this site.
Illustrative figures for demonstrating the calculation. Royalty rates and terms vary by category, market, evidence and leverage — this is the arithmetic, not an appraisal.
The pie math is only fair if the base is defined honestly. Negotiate what counts as net sales — the deductions, returns and channels — because that's where a giant quietly shrinks a "6%" into almost nothing. The rate, the base and the minimums together are what make the piece real. That — plus keeping the crown — is how you walk out fair.
Straight Answers
The questions that come up on almost every call about this idea — answered plainly, so you don't have to pick up the phone to get them.
The Language
The specific language you'll meet on this trail — grouped by where you meet it.
The chemistry and the unit
The component that does the work — the part that delivers the claimed effect.
The technology that carries and releases the active — the difference between effective and inert.
The unit form — spray, foam, cream, gel, liquid. Shaped by and shaping the chemistry and delivery.
A specialist who builds and scales the product for you.
Cost of goods sold — what one unit physically costs to make and ship.
The gap between a lab sample and a reproducible production run — where many products fail.
The proof
The existing product your formula is measured against — what "better than" means.
A trial where assessors (and often subjects) don't know which is which — removes bias.
The number of subjects — large enough that the result holds statistical weight.
Evidence backing every claim you print — "clinically proven" must survive scrutiny.
Safety testing for irritancy, sensitisation and material compatibility before efficacy claims.
Objective measurement tools — more credible than self-assessment alone.
The rules
A product whose claims are appearance/cosmetic only — the lighter regulatory lane.
A product that treats a condition without a prescription — a heavier regulatory path.
The regime governing what's allowed and claimable — e.g. the EU's 1223/2009.
The standardised ingredient naming presented on the label.
The US modern cosmetics law that tightened the FDA floor.
Each market's minimum legal bar for formula, format and claims.
The lock
A cheap filing establishing priority date; buys a year to file the full application.
Discloses the invention in exchange for a time-limited monopoly.
Composition kept confidential — but only if it stays secret and resists reverse engineering.
Protection for the brand name and identity — the consumer-facing asset.
A written, signed non-disclosure agreement — reviewed by your counsel before the meeting.
Dated, signed records of what was disclosed, to whom, and when.
The room
Renting a right to use the formula in defined markets/categories for a term — not selling it.
Your percentage of net sales — your recurring piece of the pie.
The base the royalty is paid on — its precise definition is where your share is protected or shrunk.
Guaranteed payments plus a clause returning rights if the licensee underperforms.
Being worn down and lowballed by a bigger party's resources, speed and documents.
The thing a giant can't casually dismantle — protected IP, a viable path without them, alternatives.